Fox Run Management L.L.C. cut its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 34.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,209 shares of the biopharmaceutical company’s stock after selling 13,066 shares during the period. Fox Run Management L.L.C.’s holdings in Lexicon Pharmaceuticals were worth $269,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of LXRX. BlackRock Inc. increased its position in shares of Lexicon Pharmaceuticals by 4.6% during the second quarter. BlackRock Inc. now owns 4,422,293 shares of the biopharmaceutical company’s stock worth $53,066,000 after purchasing an additional 195,461 shares in the last quarter. Price Capital Management Inc. acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at $1,352,000. UBS Group AG increased its position in shares of Lexicon Pharmaceuticals by 94.5% in the 1st quarter. UBS Group AG now owns 218,923 shares of the biopharmaceutical company’s stock valued at $1,876,000 after acquiring an additional 106,392 shares during the period. A.R.T. Advisors LLC increased its position in shares of Lexicon Pharmaceuticals by 71.0% in the 1st quarter. A.R.T. Advisors LLC now owns 54,266 shares of the biopharmaceutical company’s stock valued at $465,000 after acquiring an additional 22,533 shares during the period. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at $205,000.

NASDAQ LXRX opened at $8.77 on Friday. The company has a debt-to-equity ratio of -45.80, a quick ratio of 2.68 and a current ratio of 2.71. Lexicon Pharmaceuticals, Inc. has a 1 year low of $7.67 and a 1 year high of $13.97. The firm has a market capitalization of $1.13 billion, a P/E ratio of -6.91 and a beta of 0.35.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its earnings results on Monday, July 30th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.02. Lexicon Pharmaceuticals had a negative return on equity of 369.13% and a negative net margin of 137.32%. The firm had revenue of $13.75 million for the quarter, compared to the consensus estimate of $15.88 million. During the same period in the prior year, the firm earned ($0.33) EPS. The firm’s revenue was up 14.1% on a year-over-year basis. On average, analysts expect that Lexicon Pharmaceuticals, Inc. will post -1.38 earnings per share for the current fiscal year.

Several equities analysts recently issued reports on LXRX shares. BidaskClub downgraded Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, October 4th. ValuEngine raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 28th. Stifel Nicolaus reissued a “buy” rating and issued a $23.00 target price (down from $24.00) on shares of Lexicon Pharmaceuticals in a research report on Tuesday, July 31st. Zacks Investment Research downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 27th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, June 25th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $25.50.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

See Also: Outstanding Shares

Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX).

Institutional Ownership by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.